JACC:如何减少他汀类使用中出现的肌肉毒性等副作用?

2017-08-29 sunshine2015 来宝网

他汀类药物通过降低低密度脂蛋白或“不良”胆固醇来预防心脏病发作非常有效。然而,10%至20%的服用他汀类药物的患者报告肌肉相关症状,包括疼痛和痉挛,限制了他们使用推荐剂量。服用他汀类药物的患者心血管事件的风险很高,导致医疗保健成本上升。



研究人员确定优化解决他汀类药物治疗中肌肉症状的策略】他汀类药物通过降低低密度脂蛋白或“不良”胆固醇预防心脏病发作非常有效。然而,10%至20%的服用他汀类药物的患者报告肌肉相关症状,包括疼痛和痉挛,限制了他们使用推荐剂量。服用他汀类药物的患者心血管事件的风险很高,导致医疗保健成本上升。

为了解决这些问题,西奈山西研究人员正在为这些患者提供优化心血管风险降低的方法。研究结果将于8月28日星期一下午2点发表在美国心脏病学会杂志上。

由于不利的肌肉症状是主观的,研究团队开发了他汀类药物相关肌肉症状(SAMS)临床指标,以评估症状是否与他汀类药物相关的肌肉症状一致。

该研究的主要作者Robert Rosenson博士,医学教授,西奈山伊坎医学院心脏代谢紊乱主任说:“他汀类药物治疗患者经历的肌肉症状可能与药物无关。 “不能耐受某种他汀类药物的患者可能会耐受不同的他汀类药物。”

Rosenson和研究小组提出了SAMS患者优化胆固醇治疗的以下策略:

重新挑战以及切换他汀类药物 - 虽然切换他汀类药物并减少剂量是常见现象,但以相同剂量重新挑战使用相同他汀类药物的患者是不常见的,因为患者经常感到不舒服。研究小组建议临床医生再次尝试同一剂量的他汀类药物,以验证肌肉症状再次发生。在具有真正的他汀类药物服用症状的患者中,其他他汀类药物可能会被耐受,因为他们将经历较少的药物相互作用。

采用健康的生活方式。吃健康的饮食,保持正常体重,定期运动,避免烟草会帮助患者降低低密度脂蛋白胆固醇,这可能使他们服用剂量较低的他汀类药物。

非他汀类药物治疗服用依泽替米贝(Zetia),不同类别的胆固醇降低药物,胆汁酸螯合剂(BAS)或纤维酸药物也可降低LDL胆固醇;这些药物与不良肌肉副作用无关。

保健品。辅酶Q10可以减少SAMS,摄入姜黄可以改善肌肉骨骼病症患者的疼痛。需要进行其他试验来评估这些疗法。

原始出处:

Robert S. Rosenson, Steven Baker, Maciej Banach, et al. Optimizing Cholesterol Treatment in Patients With Muscle Complaints. Journal of the American College of Cardiology (2017). DOI: 10.1016/j.jacc.2017.07.752.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1853754, encodeId=2bbf1853e542f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Jul 04 07:35:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824253, encodeId=6ec918242530a, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Mon Sep 18 11:35:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239553, encodeId=7c5c239553c7, content=学习了学习了学习了学习了学习了学习了学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Sat Sep 02 06:30:23 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325502, encodeId=7902132550278, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Aug 31 12:35:00 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238501, encodeId=a6202385017a, content=好好看一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Wed Aug 30 06:24:20 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238443, encodeId=5110238443d1, content=学习了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuBA90ng5ibXMmibn1feGOQ2cjw0S48DKsF0icicFlmRxwHibIic2TNGd22vVqkKRMj2cRSWbpqZAPBPgdt/0, createdBy=81031668757, createdName=林3301, createdTime=Tue Aug 29 22:17:50 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
    2018-07-04 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1853754, encodeId=2bbf1853e542f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Jul 04 07:35:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824253, encodeId=6ec918242530a, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Mon Sep 18 11:35:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239553, encodeId=7c5c239553c7, content=学习了学习了学习了学习了学习了学习了学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Sat Sep 02 06:30:23 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325502, encodeId=7902132550278, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Aug 31 12:35:00 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238501, encodeId=a6202385017a, content=好好看一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Wed Aug 30 06:24:20 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238443, encodeId=5110238443d1, content=学习了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuBA90ng5ibXMmibn1feGOQ2cjw0S48DKsF0icicFlmRxwHibIic2TNGd22vVqkKRMj2cRSWbpqZAPBPgdt/0, createdBy=81031668757, createdName=林3301, createdTime=Tue Aug 29 22:17:50 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1853754, encodeId=2bbf1853e542f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Jul 04 07:35:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824253, encodeId=6ec918242530a, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Mon Sep 18 11:35:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239553, encodeId=7c5c239553c7, content=学习了学习了学习了学习了学习了学习了学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Sat Sep 02 06:30:23 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325502, encodeId=7902132550278, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Aug 31 12:35:00 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238501, encodeId=a6202385017a, content=好好看一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Wed Aug 30 06:24:20 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238443, encodeId=5110238443d1, content=学习了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuBA90ng5ibXMmibn1feGOQ2cjw0S48DKsF0icicFlmRxwHibIic2TNGd22vVqkKRMj2cRSWbpqZAPBPgdt/0, createdBy=81031668757, createdName=林3301, createdTime=Tue Aug 29 22:17:50 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
    2017-09-02 hfuym10906

    学习了学习了学习了学习了学习了学习了学习了学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1853754, encodeId=2bbf1853e542f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Jul 04 07:35:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824253, encodeId=6ec918242530a, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Mon Sep 18 11:35:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239553, encodeId=7c5c239553c7, content=学习了学习了学习了学习了学习了学习了学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Sat Sep 02 06:30:23 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325502, encodeId=7902132550278, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Aug 31 12:35:00 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238501, encodeId=a6202385017a, content=好好看一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Wed Aug 30 06:24:20 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238443, encodeId=5110238443d1, content=学习了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuBA90ng5ibXMmibn1feGOQ2cjw0S48DKsF0icicFlmRxwHibIic2TNGd22vVqkKRMj2cRSWbpqZAPBPgdt/0, createdBy=81031668757, createdName=林3301, createdTime=Tue Aug 29 22:17:50 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1853754, encodeId=2bbf1853e542f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Jul 04 07:35:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824253, encodeId=6ec918242530a, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Mon Sep 18 11:35:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239553, encodeId=7c5c239553c7, content=学习了学习了学习了学习了学习了学习了学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Sat Sep 02 06:30:23 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325502, encodeId=7902132550278, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Aug 31 12:35:00 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238501, encodeId=a6202385017a, content=好好看一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Wed Aug 30 06:24:20 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238443, encodeId=5110238443d1, content=学习了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuBA90ng5ibXMmibn1feGOQ2cjw0S48DKsF0icicFlmRxwHibIic2TNGd22vVqkKRMj2cRSWbpqZAPBPgdt/0, createdBy=81031668757, createdName=林3301, createdTime=Tue Aug 29 22:17:50 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
    2017-08-30 忠诚向上

    好好看一下

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1853754, encodeId=2bbf1853e542f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Jul 04 07:35:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824253, encodeId=6ec918242530a, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Mon Sep 18 11:35:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=239553, encodeId=7c5c239553c7, content=学习了学习了学习了学习了学习了学习了学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Sat Sep 02 06:30:23 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325502, encodeId=7902132550278, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Aug 31 12:35:00 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238501, encodeId=a6202385017a, content=好好看一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Wed Aug 30 06:24:20 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238443, encodeId=5110238443d1, content=学习了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuBA90ng5ibXMmibn1feGOQ2cjw0S48DKsF0icicFlmRxwHibIic2TNGd22vVqkKRMj2cRSWbpqZAPBPgdt/0, createdBy=81031668757, createdName=林3301, createdTime=Tue Aug 29 22:17:50 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
    2017-08-29 林3301

    学习了解了解

    0

相关资讯

JAHA:高剂量他汀类治疗能显著改善外周动脉血管疾病患者的预后!

目前,高剂量他订类药物的治疗与外周动脉疾病患者的预后是否相关尚未有过报道。近日,在国际心血管权威杂志JAHA上发表了一篇旨在评估比较低或中等剂量他汀类药物(LMI)治疗与高剂量他汀类药物(HI)治疗外周动脉血管疾病患者疗效的临床研究。本研究纳入了2006年至2013年期间行血管造影术和/或血管介入治疗的有症状的没有接受降脂药治疗的外周动脉疾病患者。高剂量他汀类药物治疗是指阿托伐他汀40-80mg或

ESC大会:接受他汀类药物治疗的女性更不容易得乳腺癌?

对一百多万人进行了14年的研究发现,高胆固醇患者乳腺癌发病率明显降低,死亡率提高。在ESC大会上提出的研究表明,他汀类药物与乳腺癌的发生率和随后的死亡率相关。

Ann Rheum Dis:强直性脊柱炎服用他汀类药物的生存获益

这项基于群体的队列研究表明,开始使用他汀类药物与AS患者的死亡风险低相关。

SCI REP:未接受他汀类药物治疗的个体维持血管功能的更佳低密度脂蛋白胆固醇水平!

由此可见,在一般人群中,LDL-C≤100毫克/分升可能是维持血管内皮功能稳定的最佳的目标水平。

Sci Rep:他汀类抗癌疗效新发现!

基尔大学领导的一项新研究表明,如何使用他汀类药物作为卵巢癌的潜在有效治疗方法。

Lancet:低密度脂蛋白究竟需要多低才是健康的?

新的分析显示,在高危人群中,达到低至低于10 mg / dL的超低LDL胆固醇水平可以安全地降低心血管事件风险。被称为PCSK9抑制剂的较新一类降胆固醇药物已经成为将LDL胆固醇显著降低至目前治疗目标以外的有效治疗方法。今年早些时候,由Brigham和女子医院调查人员进行临床试验的结果发现,当加入他汀类药物治疗时,PCSK9抑制剂evolocumab导致心血管事件风险显著降低,并且是安全的。在一个